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Cystinuria is a recessively inherited aminoaciduria that leads
to recurrent urolithiasis. It is caused by the defective
transport of cystine and dibasic amino acids in the proximal
renal tubules and intestinal epithelium. Two genes
responsible for this, SLC3A1 and SLC7A9, are known.
Patients with two SLC3A1 mutations are classified as type A
cystinuria, whereas patients with two SLC7A9 mutations are
classified as type B cystinuria. Few clinical and molecular data
have been reported for Asian cystinuria patients. In this
study, we determined the molecular basis of cystinuria in
eight unrelated Chinese subjects. Coding exons and flanking
introns of the SLC3A1 and SLC7A9 genes were directly
sequenced after amplification by polymerase chain reaction.
Five different SLC3A1 mutations were found. Two missense
mutations, D210G and S547L, were novel. The other three
SLC3A1 mutations (IVS6þ 2T4C, R181Q and R365W) have
been described previously. In addition, four novel SLC7A9
mutations, C137R, c.730delG, IVS10þ 2_3delTG and
IVS12þ 3insT, together with two previously reported
mutations (A70V and G195R) were found. All patients except
one carried compound heterozygous mutations.
IVS12þ 3insT was detected in patients from two families.
This is the first molecular genetic study on Chinese cystinuria
patients. Three patients with type A cystinuria, two with type
B cystinuria, and three carriers of type B cystinuria were
identified. Our results suggest that the molecular basis of
cystinuria is heterogeneous in our local population.
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Cystinuria (MIM220100) is a recessively inherited amino-
aciduria caused by the defective transport of cystine and
dibasic amino acids (arginine, lysine, and ornithine) in the
renal tubular and intestinal epithelial cells. Patients with
cystinuria excrete cystine amounts that are 50–200% of the
filtered load.1 Cystine has a low solubility threshold and it
precipitates easily when urine becomes more acidic and
concentrated in the renal tubules. Traditionally, cystinuria
was classified into three subtypes based on the amino-acid
excretion patterns in obligate heterozygotes. Type I cystinuria
is the fully recessive form and its heterozygotes (I/N) have
normal urinary amino-acid excretion. Type II and type III
heterozygotes (II/N, III/N), however, excrete high or
moderate amounts of urinary cystine. These carriers are at
risk of renal stone formation if the urinary cystine levels
exceed the solubility threshold.2
Two genes responsible for cystinuria have been identified.
SLC3A1, located on chromosome 2p16.3–21, was first
identified to be the cause of type I cystinuria in 1994.3 The
gene responsible for type non-I cystinuria was mapped to
chromosome 19q12–13.1 by linkage analysis4,5 and later
identified as SLC7A9 by the International Cystinuria Con-
sortium.6 The protein products of SLC3A1 (rBAT) and
SLC7A9 (b0,þ AT) form the heterodimeric amino-acid
transporter system b0,þ , which is responsible for the uptake
of cystine and dibasic amino acids in the renal tubular and
intestinal epithelial cells.7 Over 100 SLC3A1 mutations have
been identified, and all, except one (dupE5-E9), were restricted
to patients with type I cystinuria.3,8–12 At least 66 SLC7A9
mutations were known and these mutations were found in
both type I and type non-I patients.6,10,13–15 In one study, 14%
of SLC7A9 carriers have normal urinary amino-acid patterns.13
Thus, a new classification system for cystinuria was proposed,
based on the genetic defects: (i) type A cystinuria, caused by
two mutations in SLC3A1; (ii) type B cystinuria, caused by two
mutations in SLC7A9; and (iii) type AB cystinuria, caused by
one mutation in each gene.13
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Cystinuria is a global disorder and has variable prevalence
in different populations.1 This inherited disease accounts for
about 1–2% of urolithiasis in adult patients and about 6–8%
of urolithiasis in pediatric patients.1 Despite its relatively high
prevalence (B1:7000)1 and easy recognition by urine amino-
acid analysis, there were few clinical and genetic data
reported for Asian cystinuria patients. Ito et al.16 have
reported the incidence of cystinuria in Japan and investigated
36 Japanese cystinuria patients for SLC3A1 mutations.9,16 In
this study, we analyzed both the SLC3A1 and SLC7A9 genes
in a group of Chinese patients with hyperexcretion of cystine
and dibasic amino acids. The results were compared with
those reported in other ethnic groups.
RESULTS
SLC3A1 gene
Five different SLC3A1 mutations were found in patients 1–3.
Two of the five mutations were novel. Patient 1 was
compound heterozygous for a novel mutation c.629A4G
(Figure 1a) and a previously reported splice site mutation
IVS6þ 2T4C.12 c.629A4G changes the highly conserved
codon 210 from aspartate to glycine (D210G). In all, 50
control subjects were screened for this missense mutation by
a restriction enzyme method and none of them showed a
positive result (Figure 2). Patient 2 carried the second novel
mutation c.1640C4T, which changes codon 547 from
serine to leucine (S547L) (Figure 1b). He was also
heterozygous for a mutation c.542G4A (R181Q) reported
previously.3 In patient 3, homozygosity of a known disease-
causing mutation c.1093C4T (R365W) was observed
(Tables 1 and 2).17
SLC7A9 gene
Patient 4 carried two SLC7A9 mutations, c.730delG (Figure
3a), which leads to a frameshift after codon 243, and
IVS12þ 3insT (Figure 3b). Both mutations were novel.
IVS12þ 3insT was also found in patient 8 and his elder
sister in a heterozygous state. Two more novel SLC7A9
mutations, c.409T4C (Figure 3c) and IVS10þ 2_3delTG
(Figure 3d), were detected in patient 5. c.409T4C changes
the amino-acid residue at codon 137 from cysteine to
arginine (C137R). Primer-introduced restriction analysis
(PIRA)-polymerase chain reaction (PCR) did not detect this
mutation in 50 control subjects (Figure 4). Patients 6 and 7
were heterozygous for previously reported missense muta-
tions c.768G4A (G195R) and c.394C4T (A70V), respec-
tively (Tables 1 and 2).6,14
DISCUSSION
In this study, we determined the molecular basis of cystinuria
in eight unrelated Chinese subjects by analyzing the SLC3A1
and SLC7A9 genes. For patients 1–5, who were either
classified as having type I cystinuria or unclassified,
SLC3A1 was analyzed first. A negative result would be
followed by analysis of SLC7A9. Patients 6–8 were likely to be
carriers of type non-I cystinuria based on their urinary
cystine levels; hence, only the SLC7A9 gene was analyzed. Our
results showed that patients 1–3 carried two SLC3A1
mutations (type A cystinuria), patients 4 and 5 carried two
SLC7A9 mutations (type B cystinuria), whereas patients 6–8
carried a single SLC7A9 mutation (carriers of type B
cystinuria).
Figure 1 | Electrophoretograms of novel mutations in SLC3A1.
(a) c.629A4G (D210G). (b) c.1640C4T (S547L).
Figure 2 | Restriction enzyme analysis for c.629A4G in SLC3A1.
Wild-type allele has one TaqaI restriction site. The PCR product
(313 bp) will be cut into two fragments (228 and 85 bp) after TaqaI
digestion. This TaqaI restriction site is abolished in the presence of
c.629A4G, so the PCR product remains unchanged after TaqaI
digestion. A 10 ml portion of PCR product was mixed with 0.2 ml TaqaI
(20 000 U/ml; New England BioLabs, Beverly, MA), 1.5 ml 10
NEBuffer3 (New England BioLabs) and bovine serum albumin (final
concentration 100 mg/ml). The reaction mix was made up to 15 ml
with water. After an overnight incubation at 651C, the products were
electrophoresed in 4% agarose gel. Lane 2: PCR product from patient
1 after TaqaI digestion. The presence of three bands confirmed that
patient 1 was heterozygous for c.629A4G. Lane 3: PCR product from
patient 1 without TaqaI digestion. Lanes 4, 6, and 8: PCR products
from three control subjects after TaqaI digestion. The corresponding
undigested PCR products are shown in lanes 5, 7, and 9, respectively.
Lane 1: 100-bp marker.
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Six novel mutations were identified, two of them in
SLC3A1 and the other four in SLC7A9. The two novel
SLC3A1 mutations were missense mutations affecting codons
D210 and S547. Both amino-acid residues are highly
conserved among other species.18–22 Another point mutation
c.1640C4G changing codon 547 from serine to tryptophan
(S547W) has been reported in an Italian cystinuria patient.23
Using restriction enzyme analysis, D210G was not found in
50 control subjects. Therefore, we concluded that both
D210G and S547L are disease-causing mutations.
Among the four novel SLC7A9 mutations, one was a single
nucleotide deletion (c.730delG) that would lead to a frame-
shift and one was a missense mutation (C137R) that was not
detected in 50 control subjects by PIRA-PCR. The other two
novel SLC7A9 mutations, IVS10þ 2_3delTG and
IVS12þ 3insT, affect the intronic sequences. Neural Network
Analysis (http://www.fruitfly.org/seq_tools/splice.html) of
the wild-type and mutant sequences suggested that these
two mutations would abolish the normal donor splice site
and lead to mis-splicing. In particular, IVS12þ 3insT was
identified in patients from two unrelated families. Further
analysis is required to prove whether IVS12þ 3insT repre-
sents a common SLC7A9 mutation among the local Chinese
population.
Five mutations found in this study were previously
reported – SLC3A1 IVS6þ 2T4C in five Swedish patients,12
SLC3A1 R181Q in an Italian patient,3 SLC3A1 R365W in
cystinuria patients from various European countries,17,24,25
SLC7A9 G195R in an Italian patient,6 and, lastly, SLC7A9
A70V in a Caucasian patient.14 Expression study showed that
the A70V mutant allele has significant (78%) residual amino-
acid transport activity, which suggested a mild urinary
phenotype in heterozygotes.14 The relatively mild amino-
aciduria of our patient (patient 7) concurred with this finding.
The common SLC3A1 mutations identified in European
patients (e.g. T216M and M467T)26 and those reported in
Japanese patients (E268K, T341A, L346P, I445T, C673R, and
c.1820delT) were not found in this study.9,27
Among the five patients with either type A or type B
cystinuria, all except patient 3 carried compound hetero-
zygous mutations. Patient 3 was apparently homozygous for
R365W in SLC3A1, but there was no parental consanguinity.
In a study reported by Schmidt et al.,28 seven out of 49
cystinuria patients carried a large duplication in SLC3A1
Table 1 | Summary of clinical data, urinary amino-acid levels, and mutation analysis results
Urinary amino-acid levelsa
Patient Age at first stone (years) Gene Genotype Cystine (o150) Ornithine (o44) Arginine (o44) Lysine (o513)
1 4 SLC3A1 D210Vb/IVS6+2T4C 4066 5083 11 200 32 195
Father — ND 62 — — —
Mother — ND 44 — — —
2 2 SLC3A1 R181Q/S547Lb 2899 5551 9503 28 650
Father — ND 88 — — —
Mother — ND 71 — — —
3 2 SLC3A1 R365W/R365W 2351 1768 4260 9131
Father — ND Normalc — — —
Mother — ND 124 — — —
4d 7 SLC7A9 c.730delGb/IVS12+3insTb 1105 1759 3651 7089
5 25 SLC7A9 C137Rb/IVS10+2_3delTGb 2537 1476 4057 7558
6 — SLC7A9 G195R/WT 831 141 159 5030
7 — SLC7A9 A70V/WT 290 — 358 1237
Mother WT/WT — — — —
8e — SLC7A9 IVS12+3insTb/WT 999 407 486 4694
Father — ND 610 248 283 2307
Mother — WT/WT 133 35 230 345
Sisterf — IVS12+3insTb/WT 442 133 389 2599
Brotherg — ND 1954 734 902 8893
aUrinary amino-acid levels are expressed as mmol/g creatinine.
bNovel mutation.
cUrine amino acid analyzed by qualitative thin-layer chromatography.
dThis patient was taking D-penicillamine when this urine amino-acid analysis was carried out.
eThe patient was 34 months old when this urine amino-acid analysis was carried out. Previous urinary amino-acid results of this patient are listed in Figure 5.
fUrinary amino-acid analysis was carried out at the age of 6.
gUrinary amino-acid analysis was carried out at the age of 8 months.
WT: wild-type allele; ND: not done.
Table 2 | Novel mutations in SLC3A1 and SLC7A9
Gene Mutation Nucleotide change
Amino-acid
change Exon
SLC3A1 D210V c.629A4T Asp4Val 3
S547L c.1640C4T Ser4Leu 10
SLC7A9 c.730delG — Frameshift
after codon 243
7
C137R c.409T4C Cys4Arg 4
IVS10+2_3delTG c.1074+2_3delTG — —
IVS12+3insT c.1399+2_3insT — —
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spanning from intron 4 to intron 9. A large duplication like
this would be missed by PCR-based methods. Owing to the
lack of genetic information from both parents and the
limitation of our current study method, we could not exclude
the possibility of a large deletion or genomic rearrangement
in one SLC3A1 allele in patient 3.
Patient 8 showed a progressively decreasing urinary
cystine and dibasic amino-acid levels from 1 to 34 months
of age (Figure 5). Patient 8, although sharing the same
SLC7A9 genotype, had much higher urinary amino-acid
levels than his elder sister, who had the analysis carried out at
the age of 6. One possible explanation for this observation is
coinheritance of an SLC3A1 mutation in patient 8, but not in
his elder sister. Recently, Font-Llitjos et al.10 described two
asymptomatic subjects who carried one SLC3A1 mutation
and one SLC7A9 mutation (type AB). Their urinary amino-
acid levels, although they remained within the heterozygous
range,13 were higher than their family members who carried
only one mutation. To rule out the possibility of digenic
inheritance in patient 8, the SLC3A1 gene was sequenced for
this patient. No mutation could be identified in all the coding
exons and flanking introns. Therefore, we considered the
Figure 3 | Electrophoretograms of novel mutations in SLC7A9. (a) c.730delG. (b) IVS12þ 3insT (reverse sequence). (c) c.409T4C (C137R).
(d) IVS10þ 2_3delTG.
Figure 4 | Bsi WI digestion of the PIRA-PCR products. An online
software (http://cedar.genetics.soton.ac.uk/public_html/pri-
mer2.html) was used to design a pair of primers (50-CAGCCCACA-
TAGAAGGGCGTAC-30 and 50-ATCCCCGCCTACCTCTTCTCCT-30) that
amplified a 113-bp product flanking the mutation site. The primers
created a restriction site for the enzyme BsiWI when c.409T4C is
present. PCR was carried out using standard protocol with annealing
temperature at 601C. After amplification, 13.2 ml of the PCR product
was mixed with 0.3 ml of BsiWI (10 000 U/ml; New England BioLabs
Inc.) and 1.5ml 10 NEbuffer3 (New England BioLabs Inc.). The
mixture was incubated at 551C overnight. The enzyme-digested
products were then electrophoresed in 4% agarose gel. In the
presence of c.409T4C, BsiWI cleaves the PIRA-PCR product into two
fragments of 91 and 22 bp. Lanes 2 and 3: PIPR-PCR product from
patient 5 before and after BsiWI digestion, respectively. Two pairs of
undigested and digested products from control subjects are shown
in lanes 4–7. Lane 1: 100-bp marker.
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Figure 5 | Urinary cystine levels of patient 8 from 1 to 34 months
of age.
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possibility of digenic inheritance unlikely. Another possible
explanation for the phenomenon observed in patient 8 was
transient neonatal cystinuria. Transient neonatal cystinuria
was first reported by Scriver et al.29 in infants heterozygous
for cystinuria. This observation was further characterized by
Boutros et al.30 recently. Patients with types I/N, III/N, I/III,
and III/III cystinuria were found to have a progressive decline
in urinary cystine levels from the neonatal period to 2–3 years
of age. In particular, the mean urinary cystine levels of
patients with type III/N cystinuria decreased from
3621 mmol/g creatinine at 1–2 months after birth to
318 mmol/g creatinine at 4 years of age. As this decline of
urinary amino acids with age was observed in all types of
cystinuria except type I/I, the authors postulated that at least
one normal SLC3A1 allele was required to observe this
maturational effect.30 The elder sister of patient 8 in this
study had her first urinary amino-acid analysis carried out at
the age of 6. It was likely that her urinary amino-acid levels
had been stabilized before the analysis. We would expect the
urinary amino-acid levels of patient 8 to drop as he grows
older and to reach levels similar to those of his elder sister.
Long-term follow-up study of this family can confirm our
hypothesis.
In summary, this is the first study that investigated the
molecular basis of cystinuria in Chinese patients. A total of
six novel mutations, two in SLC3A1 and four in SLC7A9,
were found. Except for R365W in SLC3A1 and IVS12þ 3insT
in SLC7A9, the other nine mutations occurred only once.
Some SLC3A1 and SLC7A9 mutations were shared between
Chinese and European patients. Our findings suggest a
marked genetic and allelic heterogeneity of cystinuria in
Hong Kong Chinese.
MATERIALS AND METHODS
Patients
Eight ethnic Chinese patients were recruited in this study. None of
them had consanguineous parents or family history of urolithiasis.
Clinical data of these patients were summarized in Table 1. Urinary
amino-acid levels were expressed in mmol/g creatinine. Patients 1–4
developed cystine stones in their childhood, while patient 5 had
onset of urolithiasis at the age of 25. Their urinary cystine levels,
quantitated by reverse-phase high-performance liquid chromato-
graphy, ranged from 1105 to 4066 (normalo150). Patients 1–3 were
classified to have type I cystinuria, as their parents exhibited normal
urinary amino-acid excretions. Patients 4 and 5 remained
unclassified.
Patients 6–8 did not present with urolithiasis. Urine amino-acid
analyses were requested as part of the screening tests for metabolic
disorders. Patient 6 had mild-grade mental retardation. Her urinary
cystine levels ranged from 610 to 831. At the age of 17, she did not
have evidence of urolithiasis on ultrasound examination. Patient 7
was a female with Beckwith–Wiedemann syndrome. Mild hyper-
excretion of cystine at 290 was incidentally found. No renal stone
was detected clinically and radiologically when she was 16 years old.
Patient 8 presented with convulsion at 1 month of age.
Hyperexcretion of cystine and dibasic amino acids (cystine 2502,
ornithine 3, arginine 1299, lysine 16195) was found. Subsequent
urine amino-acid analyses remained abnormal, but showed a
progressive drop of cystine and dibasic amino-acid levels (Figure 5).
Abnormal urinary amino-acid patterns were also found in his father
(cystine 610), his elder sister (cystine 442), and younger brother
(cystine 1953). None of them have clinical signs and symptoms of
urolithiasis.
Mutational analysis of the SLC3A1 and SLC7A9 genes
Genomic DNA was extracted from peripheral blood using a
QIAamp blood kit (Qiagen, Hilden, Germany). All the coding
exons and intron–exon boundaries of SLC3A1 and SLC7A9 were
amplified by PCR. The primer sequences for both genes were
designed with reference to the genomic sequences. (Primer
sequences and PCR conditions are available from the authors on
request by email.) The PCR products were sequenced using the
BigDyeDeoxy terminator cycle sequencing reagents (Applied
Biosystems, Foster City, CA) and analyzed on an ABI Prism 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA). Novel
missense mutations were screened in 50 control subjects by either
restriction enzyme analysis or PIRA-PCR.31
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